Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free AREC Stock Alerts

Arecor Therapeutics (AREC) Competitors

Arecor Therapeutics logo
GBX 64.49 +0.99 (+1.56%)
As of 07:29 AM Eastern
Compare

AREC vs. MPH, FARN, 4BB, BVXP, and ORPH

Should you buy Arecor Therapeutics stock or one of its competitors? MarketBeat compares Arecor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arecor Therapeutics include Mereo BioPharma Group plc (MPH.L) (MPH), Faron Pharmaceuticals Oy (FARN), 4basebio (4BB), Bioventix (BVXP), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does Arecor Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than Arecor Therapeutics. Mereo BioPharma Group plc (MPH.L) is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Arecor Therapeutics£1.71M14.21-£10.68M£2.0032.25

6.0% of Arecor Therapeutics shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arecor Therapeutics has a net margin of 38.74% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Mereo BioPharma Group plc (MPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Arecor Therapeutics Neutral

Summary

Arecor Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 7 of the 8 factors compared between the two stocks.

How does Arecor Therapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

2.5% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 4.8% of Arecor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arecor Therapeutics has a net margin of 38.74% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arecor Therapeutics. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Arecor Therapeutics' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Overall Sentiment
Faron Pharmaceuticals Oy Positive
Arecor Therapeutics Neutral

Arecor Therapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Arecor Therapeutics£1.71M14.21-£10.68M£2.0032.25

Faron Pharmaceuticals Oy has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market.

Summary

Arecor Therapeutics beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does Arecor Therapeutics compare to 4basebio?

Arecor Therapeutics (LON:AREC) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
4basebio Neutral

6.0% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

4basebio has lower revenue, but higher earnings than Arecor Therapeutics. 4basebio is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M14.21-£10.68M£2.0032.25
4basebio£1.69M45.73-£9.84M-£109.00N/A

Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Arecor Therapeutics has a net margin of 38.74% compared to 4basebio's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
4basebio N/A -231.29%-54.30%

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 180.00%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Arecor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arecor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Arecor Therapeutics and 4basebio tied by winning 7 of the 14 factors compared between the two stocks.

How does Arecor Therapeutics compare to Bioventix?

Arecor Therapeutics (LON:AREC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Bioventix has higher revenue and earnings than Arecor Therapeutics. Bioventix is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M14.21-£10.68M£2.0032.25
Bioventix£12.54M6.49£8.12M£140.5211.09

6.0% of Arecor Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Arecor Therapeutics' net margin of 38.74%. Bioventix's return on equity of 65.83% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Bioventix 59.30%65.83%54.07%

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Bioventix Neutral

Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market.

Summary

Bioventix beats Arecor Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Arecor Therapeutics compare to Open Orphan?

Arecor Therapeutics (LON:AREC) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Arecor Therapeutics has a net margin of 38.74% compared to Open Orphan's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Open Orphan N/A N/A N/A

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Open Orphan Neutral

Open Orphan has higher revenue and earnings than Arecor Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M14.21-£10.68M£2.0032.25
Open Orphan£34.71M0.00N/AN/AN/A

6.0% of Arecor Therapeutics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Arecor Therapeutics beats Open Orphan on 5 of the 7 factors compared between the two stocks.

Get Arecor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AREC vs. The Competition

Export
MetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£24.35M£524.65M£6.96B£2.78B
Dividend YieldN/A3.90%2.68%6.12%
P/E Ratio32.253.1527.19368.16
Price / Sales14.216,419.21574.5584,675.62
Price / Cash5.0713.1349.2527.89
Price / Book3.8989.4010.857.59
Net Income-£10.68M-£96.07M£3.59B£5.89B
7 Day Performance-0.69%-1.83%-1.94%0.12%
1 Month Performance1.56%1.24%2.20%-1.28%
1 Year Performance31.61%54.82%23.81%62.28%

Arecor Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AREC
Arecor Therapeutics
N/AGBX 64.49
+1.6%		N/A+31.5%£24.35M£1.71M32.2510
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
FARN
Faron Pharmaceuticals Oy
N/AGBX 42
+2.4%		N/A-79.6%£85.21MN/AN/A34
4BB
4basebio
N/AGBX 550
+4.8%		GBX 1,400
+154.5%		-45.0%£85.17M£1.69MN/A101
BVXP
Bioventix
N/AGBX 1,550
-2.5%		N/A-43.4%£80.99M£12.54M11.0312

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AREC) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel